Latham & Watkins Advises Bridgepoint in Acquisition of Obagi Medical From Waldencast

Waldencast plc (Nasdaq: WALD) announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint, one of the world's leading mid-market investors. 

Latham & Watkins LLP represents Bridgepoint in the transaction with a corporate deal team led by New York partners Jane Greyf and David Allinson and Paris partner Olivier du Mottay, with associates Saïd Bakir, Meghan McDuff, and Anny Yang. Advice was provided on tax matters by New York partner Eric Kamerman, with associate Jacob Nagelberg; on intellectual property matters by New York partner Steven Betensky, with associate Alan Kim; and on benefits and compensation matters by Washington, D.C. partner Adam Kestenbaum, Washington, D.C. counsel Laura Szarmach, and London counsel Shaun Thompson, with associate Kevin Matheny.